Draft:Raktamrut in Hemophilia

{{#seo:

Keywords: Raktamrut in Hemophilia, Raktamrut in Hemophilia Research, Raktamrut in Hemophilia Ramtamrut, Raktamrut in Hemophilia Dr. Shubham Ramnarayan Dhoot, Raktamrut Vati, Raktamrut Ayurvedic Medicine Hemophilia

Raktamrut in Hemophilia is a research business founded by Dr. Shubham Ramnarayan Dhoot. The company is known for its product Raktamrut Vati, an Ayurvedic proprietary formulation described by its developer as intended for use as a supportive adjunct alongside standard Factor VIII/IX replacement therapy in patients with Hemophilia A and B. The developer states explicitly that the formulation is not a substitute for factor replacement therapy.

Background

Hemophilia is a rare, X-linked inherited bleeding disorder caused by a deficiency of Factor VIII (Hemophilia A) or Factor IX (Hemophilia B), leading to impaired blood clotting and recurrent bleeding episodes, particularly into joints, muscles, and, in severe cases, the brain. Standard management relies on replacement therapy with purified Factor VIII or IX concentrates, which the developer describes as facing challenges including high cost, treatment burden from frequent infusions, and the potential development of inhibitors that reduce treatment effectiveness, particularly in resource-limited settings.

Ayurvedic Rationale

The developer describes Hemophilia's bleeding symptoms as conceptually aligning with the Ayurvedic classification of Raktapitta, a condition attributed to vitiation of Pitta Dosha and Rakta Dhatu (blood tissue). According to this framework, aggravated Pitta destabilizes the blood-carrying channels (Raktavaha Srotas), leading to abnormal bleeding. Ayurveda also recognizes hereditary disease predisposition through the concept of Kulaja Vikara, which the developer states broadly corresponds to genetic inheritance in Hemophilia. Ayurvedic management of Raktapitta is traditionally described as involving pacification of aggravated Pitta, strengthening of Rakta Dhatu, promotion of hemostasis (Raktastambhana), and blood purification (Rakta Shodhana).

Products and Services

Raktamrut in Hemophilia focuses on research and development related to Hemophilia and offers the product Raktamrut Vati, described as a polyherbal, herbo-mineral formulation.

According to the developer, its ingredients include:

• Udumbar (Ficus glomerata) fruit and bark
• Ashwatha (Ficus religiosa) bark
• Nyagrodh (Ficus benghalensis) bark
• Swarna Bhasma (calcined gold)
• Rohitak (Tecoma undulata) bark, used in Bhavana processing
• Sariva (Hemidesmus indicus) root, used in Bhavana processing
• Krishna Tulasi (Ocimum tenuiflorum) leaf, used in Bhavana processing
• Indian cow milk, used in Bhavana processing

The developer describes the preparation process as following traditional Ayurvedic Bhavana and Mardana techniques, involving collection, authentication, premixing, wet blending with herbal decoctions and juices, controlled drying, tablet compression, and standardization under stated GMP-certified conditions.

Proposed Mechanism of Action

The developer proposes that Raktamrut Vati acts through several mechanisms, including support of natural clotting factor synthesis, hepatoprotective and splenoprotective effects, hemostatic action for minor to moderate bleeding, rejuvenative (Rasayana) effects, anti-inflammatory and analgesic action for joint bleeding, vascular strengthening, and hematopoietic support.

Clinical Observations

According to the developer, patients treated with Raktamrut Vati have shown reductions in the frequency, duration, and severity of bleeding episodes, decreased reliance on plasma-derived or recombinant clotting factors, improvements in hemoglobin levels, wound healing, and joint mobility, and no reported adverse drug reactions. These observations are presented by the developer as findings from clinical use of the formulation; the formulation is described as intended for use alongside, not in place of, standard factor replacement therapy.

Novelty and Significance

The developer describes Raktamrut Vati as the first Ayurvedic proprietary medicine developed specifically for the supportive management of Hemophilia, positioning it as an integration of Ayurvedic pathology (Raktapitta, Pandu, Vatarakta) with modern hematological understanding. The developer also frames the invention in relation to national initiatives including Make in India, Startup India, Ayushman Bharat, Atmanirbhar Bharat, Vocal for Local, and Digital India.

Leadership

The company was founded by Dr. Shubham Ramnarayan Dhoot.

Detailed Research Document

The developer describes Raktamrut Vati as "the world's first novel and clinically evidence-based Ayurvedic proprietary medicine for supportive management of Hemophilia."

Background and Purpose

According to the developer, Hemophilia is a rare, X-linked inherited bleeding disorder caused by a deficiency of specific coagulation factors. Hemophilia A, accounting for approximately 80–85% of cases, results from a deficiency of Factor VIII, while Hemophilia B is caused by a deficiency of Factor IX. This leads to recurrent, prolonged, and often spontaneous bleeding episodes, predominantly into joints (hemarthrosis), and can also affect muscles, soft tissues, and, in serious cases, the brain.

The developer notes that standard management relies on replacement therapy with purified Factor VIII or IX concentrates, and describes this approach as facing challenges in resource-constrained settings such as India, including high cost, the burden of frequent intravenous infusions, and the development of inhibitors (alloantibodies) that can render standard replacement therapy less effective, requiring costlier bypass agents.

Scientific Rationale

The developer states that Raktamrut Vati was developed to address gaps in access to clotting factor treatment, particularly in rural areas, and describes it as the first known Ayurvedic medicine designed explicitly for Hemophilia. From the Ayurvedic perspective described by the developer, Hemophilia is associated with Raktapitta, Pandu, Vatarakta, and Raktavaha Srotodushti (impairment of the blood-carrying channels), attributed to disturbance in Pitta dosha and weakening of Raktadhatu (blood tissue).

Raktamrut Vati is described by the developer as an Ayurvedic herbo-mineral formulation intended for use as an adjuvant therapy alongside standard Factor VIII/IX replacement therapy, with the stated aim of enhancing hemostasis, reducing the frequency and severity of bleeding episodes, improving joint health, and supporting Raktavaha Srotas function. The developer states this formulation is not a substitute for factor replacement therapy, but is expected to reduce the frequency of its requirement over time.

Formulation Rationale

According to the developer, the core ingredients Udumbar (Ficus glomerata), Ashwatha (Ficus religiosa), and Nyagrodh (Ficus benghalensis), collectively known as Panchavalkala, are characterized by astringent (Kashaya) taste and cooling (Shita) potency, described as supporting hemostasis (Raktastambhana) and pacifying aggravated Pitta. Rohitak (Tecoma undulata) and Sariva (Hemidesmus indicus), used in the Bhavana (wet trituration) process, are described as providing blood-purifying (Rakta Shodhana) and cooling properties. Swarna Bhasma (calcined gold) is described as a Rasayana (rejuvenative) and Balya (strength-promoting) ingredient, used alongside cow milk and Krishna Tulasi in the Bhavana process.

Proposed Mechanisms

The developer proposes that Raktamrut Vati works through the following mechanisms:

• Enhancement of natural coagulation by supporting synthesis and activation of endogenous clotting factors
• Hepatoprotective and splenoprotective action, supporting liver and spleen function relevant to clotting factor and platelet production
• Raktastambhana (hemostatic effect), described as promoting arrest of bleeding in minor and moderate hemorrhages
• Rasayana (rejuvenative) effect, described as enhancing tissue strength and immunity
• Anti-inflammatory and analgesic action for joint pain and inflammation associated with hemarthrosis
• Vascular strengthening, described as improving blood vessel elasticity and resilience
• Hematopoietic support, described as enhancing blood regeneration and hemoglobin levels

Reported Clinical Observations

According to the developer, patients treated with Raktamrut Vati have shown reductions in the frequency, duration, and severity of bleeding episodes, decreased reliance on plasma-derived or recombinant clotting factors, improvements in hemoglobin levels, wound healing, and joint mobility, and no reported adverse drug reactions. The developer describes Raktamrut Vati as intended to function as a preventive, supportive, and restorative medicine alongside the body's natural healing processes, and frames it as a potential complement to, not a replacement for, lifelong factor therapy.

The developer's stated conclusions are that Raktamrut Vati was associated with a reduction in bleeding frequency and pain intensity, and with a reduced need for factor replacement treatments, in the patients described, and that it functioned as a supportive therapy in the management of severe Hemophilia cases described.

Formulation and Preparation

According to the developer, Raktamrut Vati is composed of standardized extracts of Ficus species, Swarna Bhasma, and Bhavana Dravyas including Tecoma undulata, Hemidesmus indicus, Ocimum tenuiflorum, and Indian cow milk, prepared under stated GMP-certified conditions. The preparation process follows traditional Ayurvedic Bhavana and Mardana techniques, described as involving collection, authentication, premixing, wet blending with herbal decoctions and juices, controlled drying, tablet compression, and standardization.

Novelty Claims

The developer describes the following as novel or inventive features of Raktamrut Vati:

• Positioned as the first Ayurvedic proprietary medicine developed specifically for Hemophilia
• Framed as an integration of Ayurvedic pathology with modern hematological understanding
• Described as acting at both biomedical and Ayurvedic levels to address clotting factor deficiency and doshic imbalance
• Described as combining hepatosplenic support with hemostatic action
• Described by the developer as composed entirely of herbal constituents, free from synthetic chemicals, steroids, or preservatives, with no side effects reported in the developer's own clinical use
• Positioned by the developer as a low-cost, accessible option intended for low-resource settings, rural hospitals, and charitable organizations

Alignment with National Missions

The developer frames the invention in relation to national initiatives including Make in India, Startup India/Innovate India, Ayushman Bharat, Atmanirbhar Bharat, Vocal for Local, One Earth One Health (G20), and Digital India.

Social and Global Impact Statement

The developer describes Raktamrut Vati as intended to provide affordable, accessible healthcare for Hemophilia patients, framed as a contribution toward the vision of "From Local to Global" and "One Earth, One Health."

Product Information Document

• Formulation and Research Overview (PDF)